Phenotypic alterations in the lung epithelium have been widely implicated in chronic obstructive pulmonary disease (COPD) pathogenesis, but the precise mechanisms orchestrating this persistent inflammatory process remain unknown because of the complexity of lung parenchymal and mesenchymal architecture. To identify cell type–specific mechanisms and cell–cell interactions among the multiple lung resident cell types and inflammatory cells that contribute to COPD progression, we profiled 57,918 cells from lungs of patients with COPD, smokers without COPD, and never-smokers using single-cell RNA sequencing technology. We predicted pseudotime of cell differentiation and cell-to-cell interaction networks in COPD. Although epithelial components in never-smokers were relatively uniform, smoker groups represent extensive heterogeneity in epithelial cells, particularly in alveolar type 2 (AT2) clusters. Among AT2 cells, which are generally regarded as alveolar progenitors, we identified a unique subset that increased in patients with COPD and specifically expressed a series of chemokines including CXCL1 and CXCL8. A trajectory analysis revealed that the inflammatory AT2 cell subpopulation followed a unique differentiation path, and a prediction model of cell-to-cell interactions inferred significantly increased intercellular networks of inflammatory AT2 cells. Our results identify previously unidentified cell subsets and provide an insight into the biological and clinical characteristics of COPD pathogenesis.
Correspondence and requests for reprints should be addressed to Yu Fujita, M.D., Ph.D., The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 105-8461, Japan. E-mail: [email protected].*These authors contributed equally to this work.
Supported by Project for Ministry of Education, Culture, Sports, Science and Technology KAKENHI Grant-in-Aid for Young Scientists (A) 17H04991, Grant-in-Aid for Scientific Research (B) 21H02721, and Grant-in-Aid for Japan Society for the Promotion of Science Fellows 20J01794; a research grant from The Naito Foundation, GlaxoSmithKline Japan Research Grant, Mochida Memorial Foundation for Medical and Pharmaceutical Research, and Takeda Science Foundation.
Author Contributions: N.W., J.N., Y.F., and Y.Y. conceived and designed the study. N.W. and Y.M. performed the experiments. N.W., J.N., and Y.Y. performed the data analysis. N.W., T.K., Y.H., I.S., K.O., J.A., and K.K. interpreted the data. T.O. provided the patient samples. N.W., J.N., Y.F., J.A., and Y.Y. wrote the manuscript. Y.Y. supervised this project. All authors reviewed and edited the manuscript.
This article has a related editorial.
This article has a data supplement, which is accessible from this issue’s table of contents at www.atsjournals.org.
Originally Published in Press as DOI: 10.1165/rcmb.2021-0555OC on September 15, 2022
Author disclosures are available with the text of this article at www.atsjournals.org.
留言 (0)